Orion Corporation and Glykos Finland Oy announced that they have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates.
Orion Corporation and Glykos Finland Oy announced that they have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates.